Podcasts about hereditary cancer

Send us a textThe Modern Urologist Podcast has launched a new miniseries, Precision Oncology and Prostate Cancer: The New Standard of Care, hosted by Dr. Paul Sieber and Ashleigh Renitsky, Oncology PA. This series will focus on the evolving role of genetic testing in prostate cancer care and its impact on personalized patient treatment plans.Episode #1 - Genetic testing basicsThe first installment will provide an overview of genetic testing, highlighting the difference between germline and somatic testing, and their implications for personalized treatment. This episode emphasizes the importance of integrating streamlined testing protocols into clinical practice, understanding test results to tailor therapies for patients, and leveraging genetic counselors. 

Hereditary Cancer is a relatively recent discovery in the annals of medical science. The Li-Fraumeni Syndrome relating to a genetic mutation of the P-53 gene afflicts family members with multiple cancers for those who carry the gene. The Ingrassia family is one such case.

Dr. Aimee invites board-certified genetic counselor Natalie Richeimer to discuss the crucial intersection of genetic counseling, IVF, and cancer. Natalie explains the role of genetic counselors in the fertility space, particularly how they assist patients in understanding their risk for genetic conditions stemming from family history, personal health, or ethnicity. Dr. Aimee and Natalie talk about the important work done by JScreen, an organization providing accessible genetic testing for cancer and carrier screening. The conversation highlights the importance of understanding whether cancer is hereditary or sporadic, the implications of genetic predispositions, and how early genetic testing can impact fertility planning and treatment options. Natalie shares insights on the different types of genetic tests available, including those for embryos, and emphasizes the evolving nature and expanding role of genetic testing in family planning. They also discuss common misconceptions about genetic testing, especially among patients with a family history of cancer, and offer practical advice on how to access genetic counseling and testing through JScreen. Read the the full article on Dr. Aimee's site.  JScreen's website JScreen on Instagram Do you have questions about IVF?Click here to join Dr. Aimee for The IVF Class. The next live class call is on Monday, November 18, 2024 at 4pm PST, where Dr. Aimee will explain IVF and there will be time to ask her your questions live on Zoom.   Dr. Aimee Eyvazzadeh is one of America's most well known fertility doctors. Her success rate at baby-making is what gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org.   Other ways to connect with Dr. Aimee and The Egg Whisperer Show: Subscribe to my YouTube channel for more fertility tips!Subscribe to the newsletter to get updates

In our fourth episode, we delve into the importance of gender-inclusive language in genetic counseling and the specific challenges transgender and gender-diverse (TGD) individuals face in accessing hereditary cancer care. You can find these articles in a special virtual issue of the Journal of Genetic Counseling which is free and open access for the month of June. You can find the Journal of Genetic Counseling webpage via onlinelibrary.wiley.com or via the National Society of Genetic Counselors website.    Segment 1 “Use of gender-inclusive language in genetic counseling to optimize patient care”   Heather Motiff graduated with a B.S. in Psychology from the University of Wisconsin-Whitewater in 2006. She has extensive experience working as a crisis response advocate and co-facilitating support groups for survivors of intimate partner violence. Heather discovered her interest in genetic counseling during her first pregnancy in 2010. She has served as a Community Resource Specialist and contributed significantly to gender-affirming care initiatives during her graduate studies at UW-Madison. Heather is now an oncology genetic counselor at SSM Health Cancer Care in Madison, WI, and is dedicated to providing inclusive, quality healthcare and genetic services.   In this segment we discuss: Specific examples and terms used in gender-inclusive language. Comfort levels of genetic counselors with using gender-inclusive language. Findings from thematic analyses on the use of gendered language and its impact on patient care. Suggestions for additional training resources for healthcare professionals. Segment 2 “Experiences of hereditary cancer care among transgender and gender diverse people: “It's gender. It's cancer risk…it's everything”   Sarah Roth is a genetic counselor and a PhD candidate in Anthropology at Johns Hopkins University. She is a BRCA1 carrier whose research focuses on the experiences of patients, communities, and providers in cancer care and genomic medicine. Sarah has been a founding editor of Tendon at JHU's Center for Medical Humanities & Social Medicine, a contributing writer at Synapsis: A Health Humanities Journal, and a recent predoctoral fellow in Bioethics at the National Institutes of Health.   In this segment, we discuss: Challenges faced by TGD individuals in accessing hereditary cancer care. Participants' perspectives on gendered language in healthcare. Actionable recommendations for healthcare providers to support TGD individuals with hereditary cancer syndromes.   Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors.   Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.    For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.    Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.    DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. 

When faced with the shadows of hereditary cancer, Elizabeth Olson, a certified life coach, steps into the light with unwavering courage, sharing the deeply personal account of her BRCA2 journey. This episode takes you through the highs and lows of Elizabeth's story, as she opens up about confronting her genetic destiny after her mother's early diagnosis with breast cancer. Her tale is one of incredible resilience and the profound impact of genetic testing. It's an intimate exploration of the emotional path one must navigate when deciding on preventative surgeries, such as a double mastectomy, and the subsequent journey through reconstruction—a path marked by both emotional and physical transformations.This conversation extends beyond just one woman's story—it's a call to awareness about the importance of early screening and genetic testing, especially as breast cancer diagnoses in younger women are on the rise. Elizabeth's narrative, infused with both the gravity and grace of her experiences, is a source of inspiration and information for listeners navigating their own health journeys. It's a heartfelt reminder of the strength found in vulnerability and the empowerment that comes from informed choices. Join us as we share Elizabeth's ongoing saga, one that she promises to revisit with us, offering updates that are sure to enlighten and inspire.Connect with Elizabeth: IG: @__elizabetholson__Email: eo.abundantlifeco@gmail.comWebsite: https://www.abundantlifeco.co/Blog: https://www.abundantlifeco.co/blog-1For more information on BRCA Testing please visit: https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheetConnect with Leslie: Follow on IG: @yourjoyfulorderstyle Email: lmartinez@yourjoyfulorder.com to schedule- Speaking Events, Interviews or Life Coaching Sessions Shop my Journal (Gratitude, Goals & Prayer Journal) on Amazon:https://a.co/d/09Djvaw Read Blog Here: https://www.yourjoyfulorder.com/blog/

This week Bobbi Conner talks with Dr. Kevin Hughes about hereditary cancer and genetic testing. Dr. Hughes is Director of Cancer Genetics at Hollings Cancer Center at MUSC.

In this episode, we are joined by Dr. Ames Smith, a renowned breast cancer surgeon specializing in hereditary and genetic work with breast cancer. Dr. Smith shares his journey and how he became interested in hereditary cancer. He discusses the importance of testing for mutations and the high risk it poses for developing certain cancers. Dr. Smith also talks about his work at the Hereditary Cancer Risk Clinic and how he advises and follows up with patients who have mutations. He emphasizes that hereditary cancer is not limited to breast cancer and discusses other types of hereditary cancers such as colon, ovarian, uterine, brain, and kidney.Time Stamps with Key Takeaways:(03:34) Openness to genetic testing.(09:23) Ovarian cancer screening reliability.(13:19) Mammography and mortality reduction.(24:34])Diagnostic tools and stages.(27:35) Imaging can be wrong.(32:09) Thermography and breast cancer detection.(36:00) Breast cancer treatment advancements.(38:19) Improving functional quality of life.

Dr. Mary Nordberg with the Willis-Knighton Cancer Center discusses genetic testing and how it can help you fight cancer.

Myriad  Live episodes are recordings of an open-forum webinar hosted by Dr. Thomas Slavin. The opinions and views expressed in this recording do not necessarily represent those of Myriad Genetics or its affiliates. To participate in a future recording, visit https://myriad.com/live/ for a list of dates, times, and subjects.

Myriad  Live episodes are recordings of an open-forum webinar hosted by Dr. Thomas Slavin. The opinions and views expressed in this recording do not necessarily represent those of Myriad Genetics or its affiliates. To participate in a future recording, visit https://myriad.com/live/ for a list of dates, times, and subjects.

Dr. Ifey Stitt is a board certified OB-GYN dedicated to women's health, with special interest in genetics and education. She practices in Annapolis, Maryland and is affiliated with Luminis health where she serves as medical director for her group.

The buzz around the potential of Precision Medicine continues as new technologies, more powerful computing and our ability to store, share and interpret Big Data increases.  On this podcast Steve Coldicott and Scott Buckler chat about all aspects of the industry with patients, healthcare, industry, and research professionals about creating personalised medicines for each and every one of us. On this episode of Precision Medicine Forum Podcast, Steve's chatting with Tamara Hussong Milagre.   Tamara is the President of Evita, and passionate about her work to support families affected by Hereditary Cancer Syndromes.  You'll hear how Evita was created while Tamara was working as a nurse with a pregnant breast cancer patient.   This is the first episode to include the feature "Forward in 5 minutes", where Steve pulls out a clock and offers our guest the chance to share their thoughts on forwarding Precision Medicine.   Find out more about Evita here: https://www.evitacancro.org/ For more content, and to see many episodes of this podcast in video form, please visit out website: https://precisionmedicineforum.com/

Lynch syndrome is a common and often under-diagnosed inherited condition that increases one's risk for a variety of cancers, including colon, rectal, uterine, ovarian, urinary tract, and others. Many individuals with a Lynch mutation develop related cancers at a much younger age than the general population. According to the National Cancer Institute, “It is estimated that 1 in every 280 Americans are living with Lynch Syndrome." Most people living. with this inherited condition are unaware of it, or are diagnosed only after they have developed cancer.Dave Dubin, Founder of “Alive and Kickn”and three-time Lynch Syndrome cancer survivor shares his personal story and talks about the inspiring work his organization is doing through research, advocacy, education and screening. 

Dr. Sanjay Junega sits down with Dena Goldberg who is a genetic counselor practicing in Los Angeles. She received her Masters in Genetics and Hereditary Cancers. First and foremost, only about 10-15% of cancers are hereditary, meaning they were passed down from a parent. This means that 85-90% of cancer patients did not get it from their parents. There are many different genetic tests out there, and Dena cautions people on only using one option as it could not be complete. The most valuable aspect of speaking to a genetic counselor is the counseling aspect. The natural concern that comes with getting cancer affects people in ways they don't even realize. There is a lot of psychosocial and emotional stress that comes along with cancer risk and believing that you are at risk. There was a lady that Dena was working with who believed that she was going to die young from pancreatic cancer and did not take out a retirement fund or have kids. The night she received her genetic test explaining how low her risk actually was, she decided to have children!

Myriad  Live episodes are recordings of an open-forum webinar hosted by Dr. Thomas Slavin. The opinions and views expressed in this recording do not necessarily represent those of Myriad Genetics or its affiliates. To participate in a future recording, visit myriad-oncology.com/myriad-oncology-live for a list of dates, times, and subjects.References for this episode:https://education.asco.org/coursecollection/genetics-and-genomicsCOH-Registration now openhttps://www.cityofhope.org/education/health-professional-education/cancer-genomics-education-program/intensive-course-in-cancer-risk-assessment-overviewhttps://online.stanford.edu/programs/genetics-and-genomics-programhttps://www.nurseportfolio.org/Medical Breast Training Program - Mayo, Cleveland Clinic and Women's College of Toronto : https://ce.mayo.edu/online-education/content/medical-breast-training-program-all-sessions#group-tabs-node-course-default2https://www.ons.org/learning-libraries/precision-oncologyDiversification of Nurse Practitioner Practice: Genetic Cancer Risk Assessmenthttps://www.sciencedirect.com/science/article/pii/S1555415520301276?via%3Dihubhttps://www.duq.edu/academics/schools/nursing/faculty/grants/genomic-competencies-for-nurses-from-theory-to-application-an-online-course#:~:text=This%20professional%20development%20opportunity%20is,year%2C%20each%20spring%20and%20fall.https://myriad-oncology.com/continuing-education-webinars/The Myriad Oncology RMS team also leads a series via webinar for GC's and Nurses "Evolving Strategies in Hereditary Cancer". These can be viewed live by invitation. contact your local RMS team to get on that invite list. Also these are available on demand after the live presentation at our webpage https://myriad-oncology.com/continuing-education-webinars/https://www.gimjournal.org/multimedia/audio#:~:text=GenePod%20is%20the%20podcast%20from,content%20from%20this%20leading%20journal.

Associate Director of Genetic Counseling at the Dana Farber Cancer Institute, Jill Stopfer, Senior Genetic Counselor at the University of Texas MD Anderson Cancer Center, Jessica Corredor, and Lead Genetic Counselor for Cancer Genetics at Genome Medical, Emily Nazar, discuss the latest technological advancements and changes to delivery models, barriers in hereditary cancer genetic counseling and methods to overcome them, strategies to prepare genetic counselors for the future, and methods to improve the accessibility of genetic counseling services in hereditary cancer genetic counseling. Hosted by DNA Today's Kira Dineen.

Hereditary cancer is a topic that's been top of mind for physicians for the last 40 years. In this episode, we catch up with Dr. Jeffrey Weitzel, Natera's vice president of medical affairs, hereditary cancer, as he reflects on his life's work, his passion for teaching and onco-genetics, and the innovative work Natera is doing in the hereditary cancer space. Through genetic testing, individuals can learn if they have inherited genes that increase their chances of developing cancer. Dr. Weitzel shares how people can get more involved and proactive with their health and offers advice to clinician-teachers on the cost-effectiveness of prevention. Tune in to this episode to listen to one of the onco-genetics masterminds in the field! Click this link to the show notes, transcript, and resources: outcomesrocket.health

This week we're joined by Dr. Brian Shirts to discuss ConnectMyVariant, a service that dedicated to helping patients and families understand unique genetic variants and provides different avenues of informing family, or even people distantly related, of possible inherited risk of diseases like cancer.Dr. Shirts is an Associate Professor of Laboratory Medicine at the University of Washington. His research focuses on integrating complex genetics knowledge into clinical care. His main goal is to help prevent all hereditary cancer. He is currently working to improve strategies to help people with inherited cancer risk connect with close and distant relatives, classify rare variants, and to improve how genetic information is presented to both patients and clinicians. In his clinical role, he is one of a small group of geneticists and laboratory pathologists who supervise BROCA and ColoSeqTM tests for hereditary cancer risk at the University of Washington.On This Episode We Discuss:Common cancer genesThe importance of sharing genetic test results with family membersWhat should people consider before posting their variant online and how GINA protects themThe inspiration behind creating “Connect My Variant”Why it is helpful to connect with people who have the same variantHow genetic counselors and other healthcare providers can share “Connect My Variant” with their patientsTo connect with other individuals with the same mutations, visit the Connect My Variant message board, and to learn more about cancer genes visit The American Cancer Society and Black Cancer Genes (featured on Episode #159 of DNA Today). Check out Heather Hample's article Dr. Shirts mentioned about families in Ohio with Lynch syndrome. Keep up to date with Connect My Variant on Facebook and Instagram and connect with our guest Dr. Shirts on LinkedIn.Stay tuned for the next new episode of DNA Today on March 18, 2022! New episodes are released on the first and third Friday of the month. In the meantime, you can binge over 175 other episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Today”. All episodes since 2021 are also recorded with video which you can watch on our YouTube channel. See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, DNApodcast.com. Questions/inquiries can be sent to info@DNApodcast.com. Curious to take a peek inside your body's drug response? Then you should check out Picture Genetics' PGx Test. Powered by clinical laboratory Fulgent Genetics, Picture's PGx Test is easy to order and understand, with hassle-free clinician involvement and good looking reports! Plus you are fully supported through live chats, emails and genetic counseling. To order your Picture PGx test kit use code “DNATODAY” for 25% off and free-shipping! Get actionable genetic insights today to benefit your health tomorrow. Check out Picture Genetics' interview about pharmacogenomics with their Director of Genetic Counseling, Gregory Kellogg on episode #174 of DNA Today! (SPONSORED) PerkinElmer Genomics is a global leader in genetic testing focusing on rare diseases, inherited disorders, newborn screening, and hereditary cancer. Testing services support the full continuum of care from preconception and prenatal to neonatal, pediatric, and adult. Testing options include sequencing for targeted genes, multiple genes, the whole exome or genome, and copy number variations. Using a simple saliva or blood sample, PerkinElmer Genomics answers complex genetic questions that can proactively inform patient care and end the diagnostic odyssey for families. Learn more at PerkinElmerGenomics.com. (SPONSORED)Today I want to recommend a podcast to you called Our Opinions Are Correct hosted by Charlie Jane Anders and Annalee Newitz.Every other week, Our Opinions Are Correct dissects a different topic related to science fiction, science, and everything in between. They've talked about everything from how to write a good fight scene, to the death of the universe. Charlie Jane Anders is an award winning author of several science fiction novels, including recently released Victories Greater than Death. Annalee Newitz is an award winning science journalist who writes for The New York Times and the Atlantic. Together, they will befriend cosmic monsters! Subscribe to Our Opinions Are Correct on Apple Podcasts, and anywhere else you listen to podcasts! (SPONSORED)

AMY BYER SHAINMAN, also known as BRCA Responder, is an advocate, author, and producer providing support and education surrounding BRCA and other hereditary cancer syndromes. She's the executive producer of the award-winning documentary Pink & Blue: Colors of Hereditary Cancer. @brcaresponder Shainman is a BRCA1 gene mutation carrier and a "previvor"--meaning she is a survivor of a predisposition to cancer (a previvor is someone at extraordinarily high risk for cancer who has not had the disease). In 2010, she had two prophylactic surgeries to reduce her cancer risk drastically; a nipple-sparing, skin-sparing mastectomy with reconstruction and oophorectomy with a hysterectomy. Cure Magazine, The Jewish Journal, and The Palm Beach Post have featured Shainman's story. Shainman's medical memoir "Resurrection Lily" has won several literary awards and was the December 2020 book club selection of The National Library of Medicine. Shainman's current project is LADY. She is a producer on the scripted feature film that highlights what it's like to be a BRCA positive female at high risk of developing breast and ovarian cancer. https://www.ladypartsthefilm.com/ Say hi! @dyingoflaughter_podcast / DyingOfLaughterPodcast@gmail.com Do you like this show? Leaving a review on Apple Podcasts is extremely appreciated...I read & cherish every single one! @_ChelsWhoElse_ | www.ChelsWhoElse.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

Benjamin Preston is an award-winning business consultant and career strategist. As a consultant, he works with businesses to support initiatives in marketing, business strategy, operations, employee development, and human resources. He also offers one-on-one coaching for young professionals to create the career of their dreams. He encourages clients to uncover the unique strengths and passions of employees and build roles around them instead of taking job descriptions and fitting employees into them, He helps professionals to discover what opportunities will bring them happiness and excitement as they develop their career. His online course, Career Accelerator, is also tailored for young professionals to find freedom and excitement in the trajectory of their careers. He is the author of Harness Your Butterflies: The Young Professional's Metamorphosis to an Exciting Careerand has been featured on Ditch the Job, the Offer, Human Capital Innovations and Certifiably Unemployable for his strategic career advice. With his experience and an MBA from University of North Carolina at Chapel Hill, Benjamin can offer insightful and practical advice to his clients. Before starting his own consulting company, he worked as a marketing and business strategist for numerous companies, including native American economic development firm Ho-Chunk, Inc., NYC real estate start-up EDG/Life Coded, and Publicis Health, a billion-dollar communication conglomerate and one of the largest media companies in the world. In addition to Benjamin Preston, LLC, Benjamin is the co-founder of the Hereditary Cancer Foundation. Committed to saving the lives of individuals with cancer-causing hereditary genetic mutations, The Hereditary Cancer is a community-centered organization working to educate and support families with hereditary cancer and the physicians that combat it. Benjamin received an ELITE Entrepreneurship Award from PM360 Magazine and served as a mentor for the PRSSA chapter at the University of Nebraska-Lincoln. Born in Omaha, Nebraska, he now lives in Arlington, Virginia. Follow Ben: Website Instagram Facebook LinkedIn Twitter Youtube Medium Harness Your Butterflies Book Official Heart-repreneur® Site:  https://heartrepreneur.com

Did you know that there is a blood test that can tell you whether you are at higher risk to develop cancer during your lifetime? Today, we have Cassie Gurganus, a Certified Genetic Counselor at the USA Health Mitchell Cancer Institute, and she explains the inherited cancer risks that are passed from parent to child and the testing options that are available. Plus, she shares the latest breakthroughs and the importance of using our DNA to help diagnose, treat and further understand cancer. Key Takeaways Genetic counseling helps patients or their relatives who are at a high risk for disease to learn about their condition and possible treatments. Genetic testing can be a powerful preventative cancer tool. While all cancer involves genetic mutations, not all of those mutations are inherited. Not all genetic testing is the same. Consumer genetic testing kits like 23andMe are popular but have many limitations compared to the tests available with a Certified Genetic Counselor at USA Health.   ////// Never Miss an EpisodePlease subscribe to The Cancering Show Want us to deliver The Cancering Show to your email inbox? Let us know by contacting Dr. JYP at cancering.com.   Thanks for listening to The Cancering Show, brought to you by USA Health Mitchell Cancer Institute. Please subscribe, rate and review The Cancering Show wherever you listen to your favorite podcasts. Until next time, be healthy, happy and always thriving. USA Health Mitchell Cancer Institute The Cancering Show is brought to you by USA Health Mitchell Cancer Institute. MCI is a cutting-edge cancer research and treatment center built to fight cancer smarter in Mobile and Baldwin counties in Alabama. Our researchers and clinicians focus daily on the struggle against cancer, serving a potential catchment population of more than 4.1 million people, with a singular focus of advancing cancer diagnosis, treatment, and prevention throughout the Gulf Coast and beyond with science, technology and hope. Want to know more about the Mitchell Cancer Institute? Visit us at usamci.com or search for us on Facebook, Twitter and Instagram. Mitchell Cancer Institute is a member of USA Health. To learn more about all of USA Health hospitals, clinics and services, visit usahealthsystem.com.

Myriad Oncology Live episodes are recordings of an open-forum webinar hosted by Dr. Thomas Slavin. The opinions and views expressed in this recording do not necessarily represent those of Myriad Genetics or its affiliates. To participate in a future recording, visit myriad-oncology.com/myriad-oncology-live for a list of dates, times, and subjects.

Myriad Oncology Live episodes are recordings of an open-forum webinar hosted by Dr. Thomas Slavin. The opinions and views expressed in this recording do not necessarily represent those of Myriad Genetics or its affiliates. To participate in a future recording, visit myriad-oncology.com/myriad-oncology-live for a list of dates, times, and subjects.

In this episode of Inside the GENOME, Dr. Slavin sits down with William J. Harb, MD, FACS, FASCRS. They discuss the importance of raising awareness for colorectal cancer.About Our Guest:Dr. William Harb is a board-certified colorectal surgeon, specializing in the treatment of diseases of the colon and rectum. Through his dedication and national recognition with hereditary colorectal cancer, genetic testing has become an integral part of his practice. Dr. Harb works at the Colorectal Center in Nashville, Tennessee.  https://thecolorectalcenter.com/ 

In this episode of Inside the GENOME, Dr. Slavin sits down with Nicole Lambert, President of Myriad Genetics. They discuss her background as a genetic counselor and how she came to her role as President of Myriad, her personal story with her own genetics and risk assessment which led to her decision to undergo preventative surgery, and how Myriad is at the forefront of breast cancer risk assessment.

In this episode of Inside the GENOME, Dr. Slavin sits down with Elisabeth King, RN, FNP, AGN, AOCNP of City of Hope. They discuss the differences between training and scope among genetics professionals, and how she came into her role as a genetics provider.About Our Guest: Elisabeth King, is an Advanced Practice Provider with specialized training in genetics and is the Executive Director of Genomics and Precision Medicine at City of Hope. https://www.cityofhope.org/elisabeth-king

About This EpisodeDr. Holly Pederson is the director of the Medical Breast services in the breast center at the Cleveland Clinic. She is an Associate Professor at the Cleveland Clinic Lerner College of Medicine. She sits down with Dr. Slavin to discuss a newly emerging tool within hereditary cancer genetics: polygenic risk scores.

In this episode, Dr. Slavin sits down with Michael Hall, MD, Fox Chace Cancer Center, to discuss how he got to where he is today, his department of clinical genetics, and how he thinks COVID-19 will change the world of cancer genetics. About Our Guest: Dr. Michael Hall is Chair and Professor of the Department of Clinical Genetics at Fox Chase Cancer Center. He is a physician-scientist, medical oncologist, and an expert in gastrointestinal cancers, particularly those cause by hereditary syndromes.

[music] ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses. The European Society for Medical Oncology 2019 Congress was held in Barcelona, Spain, from September 27 to October 1. In this podcast, Dr. Ricardo Cubedo shares highlights from the meeting, including treatment advances in ovarian and lung cancer. He also discusses a new type of clinical trial known as “basket trials” and the ways they are changing the shape of cancer research. Dr. Cubedo is the Head of Sarcomas and Hereditary Cancer with the Medical Oncology Service at MD Anderson Cancer Center Madrid. He is also a member of the Cancer.Net Editorial Board. ASCO would like to thank Dr. Cubedo for discussing this research. Dr. Ricardo Cubedo: Good day, everybody. My name is Dr. Ricardo Cubedo. I am a medical oncologist from Madrid, Spain, from MD Anderson Cancer Center Madrid, and I was among the 25,000 attendees coming from all around the world, attending the last European Society for Medical Oncology Meeting, which took place between 27 September and 1st of October in Barcelona, which is a very beautiful Spanish city by the Mediterranean sea. We had a record-breaking 3,900 scientific communications, so you can bet that there is a lot to choose from, but I have chosen for you 3 topics. Two of them are relevant on their own, and very important results, and the last 1 I think it goes beyond the results themselves, changing the way we figure out things in order to fight cancer. The first item is the results of the PAOLA-1 trial, focused on advanced ovarian cancer patients. You know that ovarian cancer is the most lethal gynecological cancers, because we cannot cure it when it is diagnosed too late to remove it, usually because it is too widespread within the belly. Nowadays, those patients rely on chemotherapy in order to stop the disease, control their symptoms, and live longer. We usually use chemotherapeutics based on platinum as front-line treatment, which are just too toxic to use all the time. So the way we do it, we give the chemotherapy for some months, then stop, then used again when the disease starts progressing and the patient becomes symptomatic. Those months between one chemo period and the next one, are precious for ovarian cancer patients, because they can enjoy them free from both the burden of progressing disease and the side effects of platinum chemotherapy. The new drug that was the center of the PAOLA-1 trial is called olaparib. It is a new non-chemotherapy drug that targets directly the DNA of the tumor cells. And what it does is to prevent the DNA in the tumor cell from repairing itself when it is damaged, and that ultimately leads to the death of the tumor cell. What PAOLA-1 researchers really wanted to know is if olaparib, the new drug, was useful to delay progression once the disease was already stabilized by chemotherapy, giving patients a longer period free from chemo between 1 treatment and the next 1. That seemed a good idea, because olaparib is given as pills and has few side effects. 800, more or less, ovarian cancer patients were recruited into the trial from several countries all across Europe and were divided into 2 groups. Group number 1 were treated in the standard fashion: that is, chemotherapy until the tumor stopped, and then, maintenance with a drug called bevacizumab, which already been proven to delay the need for further chemotherapy. That is the standard. In the group B, the second group, that was the experimental group, olaparib, the new drug, was used on top of the standard treatment. Once the disease was [ceased?] with chemotherapy, patients were put on olaparib, and the results were impressive. In the control group, the median time that the cancer took to reactivate was 16 months, one-six, but the group of women treated with Olaparib didn’t need further chemotherapy for a period just shy of 2 years. Researchers even spotted a group of patients with certain mutations in the tumor DNA that achieved an astounding 37-month progression-free survival. Being able to delay a new period of chemotherapy for over 3 years is a big, big improvement for women with advanced ovarian cancer, and a very welcome new tool in our weaponry against the disease. That was the first item I wanted to discuss with you. The second one is also a clinical trial, a big clinical trial, called CheckMate 227. You know, we oncologists like to give trials those funny names. This is a trial for lung cancer patients. It is a very large study. It is still ongoing in over 300 hospitals all over the world, also in America. The non-small cell variety of lung cancer is the most common subtype of the disease and a really ruthless one. Lung cancer kills, every year, more Europeans or Americans than any other malignant tumor. So it’s no wonder that huge resources are devoted to research against this beast. Being such an aggressive disease, equally aggressive chemotherapy has been the cornerstone of its treatment, when the tumor has grown or spread beyond the reach of surgery. Again, the problem is that such overaggressive treatments like combination chemotherapy with 2 or 3 drugs at the same time, might put a temporary break on the disease but unfortunately at the expense of quality of life. What the CheckMate 227 trial explores is the role of immunotherapy. Immunotherapy, I am sure you have heard about it, is a new field of anticancer drugs, non-chemotherapy drugs, that do not attack cancer cell themselves but, instead, use some kind of molecular trickery to shake our own immune system against the tumor. The combination of 2 of such immunotherapeutic drugs, which are called nivolumab and ipilimumab, was compared in this trial to standard chemotherapy. So 1 group received the usual chemotherapy, and the other group received no chemotherapy at all, but those 2 immunotherapeutic agents combined. The results were eagerly awaited, probably the most expected results in the whole meeting, and were disclosed in Barcelona amidst much expectation at a fully packed hangar-sized conference room. The full size of the trial is suspected to be north of 2,000 individuals, but we already know what happened to the first 800 group of patients during a 2-year period, and the results are quite encouraging. Unfortunately, non-small cell lung cancer is still a deadly disease, because no matter which treatment patients received within the trial, less than half of them were still alive at the 2-year mark. But while only one-third of the patients treated with current state-of-the-art chemotherapy were alive 2 years after treatment, 40% reached the 2-year bar among those treated with immunotherapy. Moreover, and more importantly, there were hints of a small group within that 40%, approximately 2 out of every 10 patients, that stabilized for long periods of time. Something very similar, stabilization, was observed some years ago, when we started to use immunotherapy in melanoma patients. And we now know that many of those patients, stabilizing for many years, are now in fact cured, even with extensive metastasis widespread into many organs. So at first glance, CheckMate 227 results might not seem much, but they mean that, for the first time, we have proved we can treat advanced lung cancer patients without a single drop of chemotherapy, which means much better quality of life. And we have, also for the first time, a realistic prospect for a cure, more beyond mere wishful thinking. So we have seen the results of a couple of trials which are what we call “practice changing,” which means that many ovarian or lung cancer patients worldwide, should be treated in a different way, with better results, as soon as their oncologists attending the meeting fly back to their working sites. Lastly, the third piece of information I would like to share with you proves we are now right in the middle of a medical revolution. It’s not surprising if I tell you that the first thing an oncologist like me will try to figure out when faced with a new advanced cancer case is where it comes from, because we do not equally treat a breast cancer case, a stomach cancer, or lung cancer. Well, it has been so until recently. During the last decade we have learnt quite a bit about the nuts and bolts of cancer. Specific gene mutations and wrecked proteins are both the hallmarks of cancer cells and targets for new drugs. I will give you an example: several years ago researchers found a protein called HER2 on the surface of cancer cells in 2 or 3 out of every 10 breast cancer patients. What this protein does is to rev up the cell’s machinery keeping it in constant multiplication and leading to fast tumor growth, so those were patients with very bad prognosis, as the tumor that grows rapidly, also spreads rapidly. But a new drug called trastuzumab was tailored to disable HER2, the protein that was accelerating the tumor cell, and that made a huge leap in the treatment of HER2-positive breast cancer patients. But the white-coated guys at the research labs showed us that HER2 was not only present in breast cancer, but also in subsets of gastric, lung, ovary, womb, bladder, colon, and head and neck tumors, which was quite surprising, because those are completely unrelated malignancies. Nowadays, trastuzumab, the breast cancer drug, is also used to treat gastric tumors and is beginning to raise interest in the lung cancer arena too. Well, inspired by those facts, some brave oncologists began to think out of the box and wondered if all we really need to know is the mutations and other molecular characteristics of the tumors in order to select treatments targeted against them, no matter where the cancer comes from. To treat in the same way, a colon cancer, a thyroid cancer, a breast cancer, or a brain cancer, provided they have the same molecular basis. Well such ideas were so revolutionary, they raised a few eyebrows and a lot of skepticism, but, well, this is science and we do not dismiss ideas without some previous research. Thus, the so-called “basket trials” were designed and carried out. Patients in such “basket trials” were hand-picked based on specific mutations and put to treatment, just like one chooses ripe berries and collects them into the basket. The result of such ground-breaking trials proved that the concept was right. In this Barcelona meeting, Dr. Christian Dittrich from Vienna presented us with the combined results of 2 basket studies: the SCOUT and the NAVIGATE trials. Both explore the activity of a new drug called larotrectinib, in patients with any kind of cancer, provided their tumors had a mutant form of a protein called TRK. When healthy, TRK proteins are essential for a healthy brain and nervous system. But once mutated, TRK leads to cancer in several organs. And that was the basis of the trial. The new drug, larotrectinib, is carefully designed to disable the mutated TRK proteins while sparing the healthy ones you need. Both clinical trials combined included, more or less 160 patients, from children under 1 year to 84 year old adults. The results presented at the meeting in Barcelona were rewarded with the general applause from the audience, because they were astounding. 80% of the patients responded to the drug, more than thee-quarters of them still without signs of any health deterioration 1 year after they were given their first dose. Such results are really remarkable, as we are speaking of a group of patients diagnosed with no less than 18 different types of cancer, treated with a single drug, many of them having failed to several previous treatments or resistant to any known therapy. Those results are not practice changing, because we have to resolve a lot of questions first, but are very exciting because they open a new drug for cancer treatment. After a good medical meeting you go back home with some answers. But after a really good one you collect many more questions than answers. Are we going to treat patients based on their tumor genetics instead on classical tumor types? How are new treatments to be combined? Which ones should be given frontline, which ones after progression? What genes should be checked in tumor biopsies on a routine basis? Are there late side effects still to be seen from the new drugs? When to stop maintenance treatments? Are some long-lasting responders really cured of their cancer? How are we going to pay for the new ultra-expensive fancy drugs, some of which are to be maintained for years, even lifelong? Many, many questions to answer. One thing I assure you: these are thrilling times to be an oncologist. I thank you all for your attention. ASCO: Thank you, Dr. Cubedo. Listen to more research highlights from scientific meetings: subscribe to Cancer.Net Podcasts on Apple Podcasts or Google Play, or visit www.cancer.net. This Cancer.Net podcast is part of the ASCO Podcast Network. This collection of 9 programs offers insight into the world of cancer care, covering a range of educational, inspirational, and scientific content. You can find all 9 shows, including this one, at podcast.asco.org. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds breakthrough research for every type of cancer, helping patients everywhere. To help fund Cancer.Net and programs like it, donate at conquer.org/support. [music]

Amy Byer Shainman, also known as the BRCA Responder, is a BRCA1 mutation carrier and previvor as well as a passionate patient advocate providing education and support for others with BRCA mutations and other hereditary cancer syndromes. Amy has appeared in numerous news articles and television segments sharing her story while stressing how important certified genetic counseling is in the genetic testing equation. She is the Executive Producer of the award winning BRCA documentary Pink & Blue: Colors of Hereditary Cancer, and an administrator of the Facebook Group BRCA Sisterhood, which has over 10,0000 members. She recently published a health and medical memoir, Resurrection Lily: The BRCA Gene, Hereditary Cancer, & Lifesaving Whispers from the Grandmother I Never Knew. Have thoughts or a related story you’d like to share? Leave us a short voice message here! We may use your message on a future show. Links and Resources Amy’s website: BRCA Responder Buy Resurrection Lily through Indiebound Watch Pink and Blue: Colors of Hereditary Cancer through Google Play or iTunes. Lady Parts The Film Connect with Amy on Social Media: Amy on Twitter: @BRCAResponder BRCAResponder on Instagram: @brcaresponder Amy on Facebook Amy on LinkedIn Buy Pretty is What Changes through Indiebound Check out other Patient Stories podcast episodes. Read other Patient Stories on the Grey Genetics Patient Stories Page Do you want to support Patient Stories? Make a donation online! Want to support Patient Stories in a non-monetary way? Leave us a review on iTunes, or share your favorite episodes on Social Media. Patient Stories on Twitter: @GreyGeneticsPod Patient Stories on Instagram: @patientstoriespodcast Are you looking for genetic counseling? Patient Stories is sponsored by Grey Genetics, an independent telehealth genetic counseling and consulting company. Book an appointment with a genetic counselor specialized in your area of concern. All genetic counseling appointments take place over secure, HIPAA-compliant video-conferencing or by phone. Not quite ready for genetic counseling but still looking for guidance? Check out our new family history review services here.

Dan Head knew he had a genetic predisposition to cancer after his father was diagnosed with colon cancer and was on a preventative path leading up to his diagnosis—thus catching the cancer at an earlier, more treatable phase. Dr. Matt Yurgelun, director of the Lynch Syndrome Center at Dana-Farber joins Dan and OMF to discuss hereditary predispositions to cancer and his research.

ONS member Suzanne Mahon, RN, DNSc, AOCN®, AGN-BC, clinical nurse specialist and professor at Saint Louis University in Missouri, joins Chris Pirschel, ONS staff writer, to discuss her ONS Congress presentation on hereditary cancer genetics, collaborating with genetic professionals, and how genetic testing influences cancer prevention and care. Music Credit: "Fireflies and Stardust" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 3.0 License http://creativecommons.org/licenses/by/3.0 Episode Notes: Check out these resources from today's episode: Complete this evaluation for free nursing continuing professional development. Episode 13: What You Need to Know About At-Home Genetic Testing Hereditary Cancer Genetics 101 presentation from the ONS 44th Annual Congress What Genetics Means in Hereditary Cancer Genetics and genomics articles from the Clinical Journal of Oncology Nursing Genetics and genomics articles from ONS Voice

When Vicki was diagnosed with breast cancer for the third time at age 47, she was finally offered genetic testing and learned she carried a mutation in the BRCA2 gene. When her brother Harvey learned there was a 50/50 chance he could be carrying the same mutation, he didn’t think too much about it. Two years later, he felt a lump in his breast and was diagnosed with breast cancer. 18 months later, he was diagnosed with prostate cancer. After experiencing how hard it was to find information and support related to breast cancer in men, Harvey and Vicki were driven to found HIS Breast Cancer. They are passionate about reframing breast cancer not as a woman’s disease but as a human disease that affects both men and women. Links and Resources HIS Breast Cancer Facing Our Risk of Cancer Empowered (FORCE) Harvey’s book on Amazon: Sir! You Have Breast Cancer Documentary Pink & Blue: Colors of Hereditary Cancer on iTunes and on Amazon. Connect with HIS Breast Cancer on Social Media: HIS Breast Cancer on Twitter: @hisbreastcancer HIS Breast Cancer on Instagram: @HISbreastcancer HIS Breast Cancer on Facebook Check out other Patient Stories podcast episodes. Read other Patient Stories on the Grey Genetics Patient Stories Page Do you want to support Patient Stories? You can now make a donation online! Want to support Patient Stories in a non-monetary way? Leave us a review on iTunes, or share your favorite episodes on Social Media. Patient Stories on Twitter: @GreyGeneticsPod Patient Stories on Instagram: @patientstoriespodcast Are you looking for genetic counseling? Patient Stories is sponsored by Grey Genetics, an independent telehealth genetic counseling and consulting company. Book an appointment with a genetic counselor specialized in your area of concern. All genetic counseling appointments take place over secure, HIPAA-compliant video-conferencing or by phone.

We’re excited to talk to Alan Blassberg who directed and produced the documentary:"Pink & Blue: Colors of Hereditary Cancer". In 2004, Alan launched his own production company, First Prize Productions. Pink & Blue is his first documentary directorial debut. Pink and Blue shines a light on the BRCA mutations and the experience of women and men making decisions to keep themselves healthy. In this documentary, Alan also tells his own story of being a BRCA2 positive male to highlight the experience of those who are at risk of male breast cancer.

Why is cancer called a genetic disease and what does that mean for you? Julie McCrossin chats to genetic oncologist Dr Hilda High about what genetic tests can tell us about cancer. Listen now to find out more. See omnystudio.com/listener for privacy information.

Tamar Goldwaser, MD

Mel sits down with #HCCHAT leaders Amy, Ellen and Georgia to talk about the upcoming Moonshot and what it means for Hereditary Cancer. The #HCCHAT #Moonshot tweetchat on June 29th at noon will feature Vincent T Devita Jr. MD, Head of the NCI during Nixon's Cancer Act. Don't miss this episode and make sure you are a part of history during the #HCCHAT on June 29th.

Dr Lancaster talks to ecancertv at SABCS 2015 about the myRisk® Hereditary Cancer test. This test consists of a 25-gene panel that identifies an elevated risk for eight important hereditary cancers: breast, ovarian, endometrial, prostate, gastric, colorectal, pancreatic and melanoma. Dr Lancaster notes that one of the potential barriers to testing for hereditary cancer is that it may cause distress to the individual being tested and so some patients and clinicians may be wary. Interim data on several hundred patients suggests, however, that this does not appear to be a significant problem with the use of the myRisk® test and patients noted that they were quite pleased that they agreed to being tested and had no regrets. He also discusses the advantages of testing for multiple rather than single genes for identifying different risk categories of patients, and how 40% of mutated genes in breast cancer appear over the age of 45 years so using that age as a cut off would mean missing a lot of women who may go on to develop the disease or secondary cancers.

About 10 percent of all incidences of cancer are caused by inherited gene mutations which increase the risk for developing certain types of cancer. People living with these inherited gene changes also have a 50 percent chance of passing the mutation down to their children. For people living with this high risk, it's important to know the facts, how to manage this risk and what treatment options are available. Joining guest host Linda House to discuss living with the risk of developing hereditary cancer is Lisa Schlager, Vice President of Community Affairs for Facing Our Risk of Cancer Empowered (FORCE) and Karen Hurley, a licensed clinical psychologist specializing in hereditary risk counseling.

Robin Schwartz shares her experience as a hereditary cancer genetic counselor. As a genetic counselor for over 30 years she has seen many changes in the field and provides an inside scoop. She provides information to patients who are interested in genetic counseling and how patients can prepare for a genetic counseling meeting. We discuss red flags for hereditary cancer, genetic testing, and how insurance coverage works with the cost of these services. Check out nsgc.org, mentioned by Robin Schwartz, to learn more about genetic counselors.

Georgia Hurst (@ShewithLynch), Amy Byer Shainman (@BRCAresponder), and Ellen Matloff (@MyGeneCounsel) are involved in raising awareness for Hereditary Cancer by holding the #Hcchats (@Hc_chat) on Twitter. You can catch the next Tweetchat April 29th at 9pm ET with special guest Dr. Sharon Bober (@DrSharonBober), an expert in sex after Oophorectomy or Hysterectomy. Georgia Hurst shares her and her family's experience having Lynch Syndrome and how she started her non-profit, IHaveLynchSyndrome.com. Amy Byer Shainman describes her documentary, Pink and Blue, and being a BRCA1 positive previvor. Ellen T. Matloff is the President and CEO of MyGeneCounsel and shares her insight on the importance of understanding genetic testing and genetic counseling and we all weigh in on Angelina Jolie's impact on both.

On this Episode of The Cancer Warrior prior guests Amy Byer Shainman, executive producer of the Hereditary Cancer documentary Pink and Blue. And Genetic Counselor Ellen T. Matloff join Georgia Hurst, a lynch syndrome patient and advocate for those with hereditary cancer syndrome join Mel on the show to talk about The Angelina Effect, genetic testing, and the Lynch Syndrome.

We've all said it—“oh you must have bad luck,” or “don't worry this could have happened to anyone.” And for some people diagnosed with cancer, this is the case. But in 10 percent of cancer incidences it's no bad luck or coincidence—it's genetics. Guest host Linda House is joined by Annie Parker and Lillie Shockney two extraordinary women with extraordinary stories who, in a time before the discovery of the BRCA1 gene, knew the cancer that was impacting their families, and later themselves, was no coincidence. Today they each are dedicating their lives to helping and educating others about hereditary breast cancer.

About 10 percent of all incidences of cancer are caused by inherited gene mutations which increase the risk for developing certain types of cancer. People living with these inherited gene changes also have a 50 percent chance of passing the mutation down to their children. For people living with this high risk, it's important to know the facts, how to manage this risk and what treatment options are available. Joining guest host Linda House to discuss living with the risk of developing hereditary cancer is Lisa Schlager, Vice President of Community Affairs for Facing Our Risk of Cancer Empowered (FORCE) and Karen Hurley, a licensed clinical psychologist specializing in hereditary risk counseling.

Host: Matt Birnholz, MD Dr. Andrew Wagner, Associate Professor of Obstetrics and Gynecology at the University of Oklahoma Health Sciences Center, joins host Dr. Matt Birnholz to discuss the roles of the OB/GYN as both primary care providers and specialists in screening, diagnosing, and treating hereditary cancer syndromes in women. Their discussion covers cancers of the breast, ovaries, endometrium and cervix, as well as related heriditary conditions such as Lynch Syndrome.

September 28, 2011 Join host Dr. Tim Cripe with his co-hosts Drs. Jim Geller, Lionel Chow, and Lars Wagner in a robust discussion with special guest Dr. Kathryn Wikenheiser-Brokamp on the implications of DICER1, rare tumor registries, and difficult issues surrounding genetic counseling. Kathryn A. Wikenheiser-Brokamp, MD, PhD, is an Associate Professor in Pathology and Pulmonary Biology at Cincinnati Children's Hospital Medical Center. Her research is focused on pediatric and adult lung diseases, including cancer. She seeks to determine the molecular mechanisms underlying Rb/p16, p53, and Dicer1 pathway function in lung development and the pathogenesis of lung disease. Dr. Wikenheiser-Brokamp holds a PhD in Developmental Biology, Developmental Biology and an MD from University of Cincinnati. Papers discussed: DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J Med Genet. 2011 Apr;48(4):273-8. Extending the Phenotypes Associated with DICER1 Mutations. Hum Mutat. 2011 Aug 31. doi: 10.1002/humu.21600. Ovarian sex cord-stromal tumors, pleuropulmonary blastoma and DICER1 mutations: a report from the International Pleuropulmonary Blastoma Registry. Gynecol Oncol. 2011 Aug;122(2):246-50. Please send questions or comments to twipo@solvingkidscancer.org

Joshua D. Schiffman, MD, Huntsman Cancer Institute, University of Utah, discussing the connection of molecular pathways to hereditary cancer risk syndromes.

On this episode, the second installment of CSC's “Hereditary Cancer and Genetics” radio series, Kim explores hereditary cancer and genetic testing, focusing specifically on Lynch Syndrome. Joined by Cindy Robinson, a colorectal cancer survivor who tested positive for Lynch Syndrome in 2007, and Jill Stopher, a certified genetic counselor at the Abramson Center at the University of Pennsylvania, Kim and her panelists explore the realities of Lynch Syndrome and the decision-making process involved with genetic testing.

On this episode, the second installment of CSC's “Hereditary Cancer and Genetics” radio series, Kim explores hereditary cancer and genetic testing, focusing specifically on Lynch Syndrome. Joined by Cindy Robinson, a colorectal cancer survivor who tested positive for Lynch Syndrome in 2007, and Jill Stopher, a certified genetic counselor at the Abramson Center at the University of Pennsylvania, Kim and her panelists explore the realities of Lynch Syndrome and the decision-making process involved with genetic testing.

In this episode, Kim Thiboldeaux is joined by 2 guests for a discussion on hereditary cancer, focusing specifically on breast and ovarian, and genetic testing. Guests include Kate Stern Gonzalez, a person who is living with a BRCA1 gene mutation, and Dr. Karen Hurley, a clinical psychologist who supports people at risk of hereditary cancer. Specific discussion topics include: understanding risk for developing hereditary cancer, decision-making surrounding genetic testing, and finding social and emotional support when confronted with the possibility of carrying a genetic mutation.